Good news, but is it as sensational as others are posting this
morning?
Isnt it just another positive sign that the new formulation has the same potential as the old one ( with the added benefits of the means of administration via IV) and is therefore on track to get into the clinic as per the current (latest) plan?
Am I missing something spectacular here? I note we now get the $ benefits of ODD in the US as well.
Be nice to see another price bump on the back of this. I’d love to see us back above $2 for good.
Ann: US FDA Orphan Drug Designation Awarded to RC220 Bisantrene, page-17
-
- There are more pages in this discussion • 94 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.060(3.79%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.54 | $1.56 | $1.53 | $130.2K | 84.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4993 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 10451 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |